Long-term predictive value of serum PSA values obtained in clinical practice – Results from the Norwegian Prostate Cancer Consortium (NPCC)
Stefan Carlsson(Immunitas Therapeutics (United States)), Jan Oldenburg(Akershus University Hospital), Stefan Müller(University of Freiburg), Ola Bratt(Sahlgrenska University Hospital), Kirsti Aas(University of Oslo), Hans Lilja(Memorial Sloan Kettering Cancer Center), Andreas Stensvold(Østfold Hospital Trust), Johan Bjerner, Olivier Thomas(Laboratoire d’Ingénierie des Systèmes Physiques et Numériques), Christoph Müller(Sørlandet Sykehus), J. Walz, S. D. Fosså(Oslo University Hospital), Oluf Dimitri Røe(Norwegian University of Science and Technology)
Cited by 0
Related Papers
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
|Clinical Chemistry|2008|1.1k
Molecular cloning of human prostate specific antigen cDNA
|FEBS Letters|1987|394
Testicular Cancer Survivorship: Research Strategies and Recommendations
|JNCI Journal of the National Cancer Institute|2010|289
Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study
|European Urology|2014|253
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma
|Journal of Clinical Oncology|2018|229